

1 **In Vitro Expansion of Keratinocytes on Human Dermal Fibroblast-Derived Matrix**
2 **Retains Their Stem-Like Characteristics**

3

4 **Chee-Wai Wong**^{1,2}, Beverley F. Kinnear^{1,2}, Radoslaw M. Sobota^{3,4}, Rajkumar Ramalingam⁴,
5 Catherine F. LeGrand^{1,2}, Danielle E. Dye^{1,2}, Michael Raghunath⁵, E. Birgitte Lane⁴, and
6 Deirdre R. Coombe^{1,2,6}

7

8 ¹School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin University,
9 Bentley, WA 6102, Australia;

10 ²Curtin Health Innovation Research Institute, Faculty of Health Science, Curtin University,
11 Bentley, WA 6102, Australia;

12 ³Institute of Molecular and Cell Biology, Agency for Science, Technology and Research
13 (A*STAR), 61 Biopolis Drive, No. 07-48A Proteos, Singapore 138673, Singapore;

14 ⁴Institute of Medical Biology, Agency for Science, Technology and Research (A*STAR), 8A
15 Biomedical Grove, No 06-06 Immunos, Singapore 138648, Singapore;

16 ⁵Centre for Cell Biology and Tissue Engineering, Competence Centre for Tissue Engineering
17 and Substance Testing (TEDD), Institute for Chemistry and Biotechnology, ZHAW School
18 of Life Science and Facility Management, Zurich University of Applied Science, Switzerland

19 ⁶Centre for Cell Therapy and Regenerative Medicine, School of Biomedical Sciences, The
20 University of Western Australia, Crawley, WA

21

22 * Corresponding Author

23 Deirdre R Coombe

24 Email: D.Coombe@exchange.curtin.edu.au

25 Keywords: Extracellular matrix, keratinocytes, adult stem cells, serum-free culture,
26 xenogeneic-free culture, self-renewal

27

28 Running Title: Dermal ECM Regulates Keratinocyte Behaviour

29

30 **Summary:**

31 The long-term expansion of keratinocytes under serum- and feeder free conditions
32 generally results in diminished proliferation and an increased commitment to terminal
33 differentiation. Here we present a serum and xenogeneic feeder free culture system that
34 retains the self-renewal capacity of primary human keratinocytes. *In vivo*, the tissue
35 microenvironment is a major contributor to determining cell fate and a key component
36 of the microenvironment is the extracellular matrix (ECM). Accordingly, acellular
37 ECMs derived from human dermal fibroblasts, cultured under macromolecular
38 crowding conditions to facilitate matrix deposition and organisation, were used as the
39 basis for a xenogeneic-free keratinocyte expansion protocol. A phospholipase A₂
40 decellularisation procedure produced matrices which, by proteomics analysis,
41 resembled in composition the core matrix proteins of skin dermis. On these ECMs
42 keratinocytes proliferated rapidly, retained their small size, expressed p63, did not
43 express keratin 10 and rarely expressed keratin 16. Moreover, the colony forming
44 efficiency of keratinocytes cultured on these acellular matrices was markedly enhanced.
45 Collectively these data indicate that the dermal fibroblast-derived matrices support the
46 *in vitro* expansion of keratinocytes that maintained stem-like characteristics under
47 serum free conditions.

48

49

50 **Introduction**

51 The skin is an indispensable barrier that safeguards the body from the external
52 environment. It possesses the ability to self-renew, which enables the replacement of
53 dead cells and the repair of wounds thereby sustaining a barrier function[1]. In normal
54 circumstances, most cutaneous wounds heal without medical intervention. However, if
55 the wound is extensive and extends into the dermis, medical attention may be
56 required[2]. Traditionally, the therapeutic strategy for treating large, deep wounds has
57 been to use split-thickness skin autografts. However, this treatment is not viable in the
58 case of extensive burn injury, as patients may lack sufficient healthy donor sites[3].

59

60 The grafting of cultured keratinocytes is an alternative treatment to assist in the repair
61 of damaged skin. This method uses a technique originally developed by Rheinwald and
62 Green[4] to expand keratinocytes *in vitro* from a patient's skin biopsy. In this method,
63 expansion of keratinocytes is achieved using an irradiated mouse fibroblast feeder layer
64 and medium containing foetal bovine serum (FBS). While this is effective for rapidly
65 expanding keratinocytes, the reliance on xenogeneic components carries a potential risk
66 of exposing patients to animal pathogens and immunogenic molecules[5]. To address
67 these concerns, *in vitro* culture systems that omit both the feeder layer and serum were
68 developed. A popular system uses a defined serum-free medium that contains the
69 necessary growth factors and a collagen matrix to support keratinocyte attachment and
70 growth[6, 7].

71

72 While this defined culture system may meet regulatory approval, its ability to propagate
73 keratinocytes is inferior to the Rheinwald and Green[4] system. Keratinocytes grown
74 in the defined serum-free system have a more limited lifespan; a diminished self-

75 renewal capacity and an increased commitment towards differentiation or
76 senescence[7, 8]. This suggests that the defined serum-free system does not fully meet
77 keratinocyte requirements. It is likely crucial elements required to sustain
78 undifferentiated keratinocytes long term, reside in the fibroblast feeders used in the
79 Rheindwald and Green system. Fibroblasts secrete cytokines, growth factors and
80 extracellular matrix (ECM). The focus for defined culture systems has been on the
81 cytokines and growth factors[9, 10], but it is possible the ECM is a crucial requirement
82 that has been overlooked.

83

84 The ECM is complex meshwork of macromolecules, comprising fibrous structural
85 proteins (e.g. collagen, fibronectin, laminin and elastin), specialised proteins (e.g.
86 growth factors) and proteoglycans (e.g. perlecan). It was previously thought to be an
87 inert structure that provided a platform for cell adhesion, but it is now known that the
88 ECM provides both biochemical and biomechanical cues that regulate cell behaviours
89 such as adhesion, migration, proliferation and differentiation[11, 12]. Currently, there
90 is considerable interest in using cell-derived matrices to reproduce a tissue specific
91 microenvironment. Numerous studies have shown that acellular ECM assists in
92 maintaining the stem cell phenotype and in promoting self-renewal during *in vitro*
93 expansion[13-16]. However, keratinocyte expansion on a dermal fibroblast derived-
94 matrix (Fib-Mat) under serum free conditions has not been well examined.

95

96 While it is possible to generate an acellular ECM *in vitro*, most culture methods produce
97 an unstructured ECM that lacks critical components[17, 18]. This may be due, in part
98 to differences between the *in vitro* and *in vivo* microenvironments. Cells in culture are
99 in a dilute solution of macromolecules of 1-10 mg/ml, which is several-fold lower than

100 the normal physiological environment that can range from 20.6 to 80 mg/ml[19]. Thus,
101 in culture, molecular interactions in the extracellular environment may not be sufficient
102 to produce an ECM which resembles that seen *in vivo*. To mitigate this problem, the
103 addition of large, inert macromolecules such as FicollTM to the culture medium has been
104 used to mimic the density of macromolecules within tissues. Molecules like FicollTM,
105 when used in this context, have been called “macromolecular crowders” (MMC) and
106 the process of mimicking the *in vivo* concentration of macromolecules is called
107 “macromolecular crowding”. Interestingly, the addition of FicollTM to cell cultures was
108 found to accelerate biochemical reactions and supramolecular assembly, and
109 macromolecular crowding was found to affect the deposition and architecture of the
110 ECM[17, 18, 20].

111

112 Here, we describe the development and functional characterization of a xenogeneic-
113 free matrix derived from primary human dermal fibroblasts (Fig 1). A proteomics
114 analysis confirmed that this matrix resembled, in its core protein composition, the ECM
115 of human dermal tissue. When used as a substrate for keratinocyte growth in the
116 absence of feeder cells and under defined serum-free conditions this Fib-Mat facilitated
117 keratinocyte proliferation. In addition, more keratinocytes maintained the stem-like
118 characteristics of small cell size, expression of p63 and a lack of keratin 16 expression
119 as well as the retention of a colony forming capability. These data indicated that these
120 acellular Fib-Mat are an appropriate microenvironment to enable the expansion of
121 undifferentiated keratinocytes *in vitro*.

122

123

124

125

126 **Materials and Methods**

127 **Antibodies**

128 The primary rabbit polyclonal antibodies used were anti-type I collagen (Abcam;
129 Cambridge, UK), anti-type IV collagen (Abcam), anti-fibronectin (Abcam) and the
130 anti-perlecan antibody CCN-1 was a gift from Prof. John Whitelock (University of
131 NSW, Sydney, Australia). The mouse monoclonal antibodies (mAbs) used were: anti-
132 fibroblast marker (clone TE7; Millipore; MA, USA), anti-involucrin (clone SY5;
133 Sigma; MO, USA), anti-ki67 (clone MM1; Novacastra; Wetzlar, Germany), anti-p63
134 (clone 4A4; Abcam), anti- α -smooth muscle actin (clone 1A4; Sigma), anti-Thy1 (BD
135 Bioscience; NJ, USA), and anti-vimentin (clone V9; Dako; CA, USA). The following
136 mouse mAbs: anti-keratin 10 (K10, clone LH2), anti-keratin 14 (K14, clone LL001)
137 and anti-keratin 16 (K16, clone LL025) were produced in house. The secondary
138 antibodies used were Alexa488 anti-mouse IgG, Alexa546 anti-mouse IgG, Alexa 488
139 anti-rabbit IgG and Alexa546 anti-rabbit IgG (all from Molecular Probes,
140 ThermoFisher Scientific; OR, USA).

141

142 **Cell cultures**

143 Two human dermal fibroblast (HDF) donors were used, one cell population was
144 obtained from the American Type Culture Collection (ATCC; VA, USA) and the other
145 was from the Skin Cell Bank of Institute of Medical Biology, Singapore, and the use of
146 these cells was covered by ethical codes overseen by Curtin University Human Ethics
147 committee (ethics approval number: HRE-2016-0273A). HDFs were maintained in
148 Dulbecco's Modified Eagle's medium (DMEM) supplemented with 10% FBS (Serana
149 Europe GmbH; Pessin Germany), 10 mM HEPES, 2 mM L-glutamine and 1 mM
150 sodium pyruvate (Gibco. ThermoFisher Scientific). Human neonatal keratinocytes

151 (purchased from Gibco) were cultured on tissue culture growth surfaces that have been
152 coated with type I collagen (Sigma) in PBS ($3\mu\text{g}/\text{cm}^2$) and maintained in Defined
153 Keratinocyte Serum Free medium (DKSFM; Gibco). Cells were maintained in tissue
154 culture incubators at 37°C and 5 % carbon dioxide. Keratinocytes at passage 4 or 5
155 were used for all experiments.

156

157 **Extracellular matrix deposition with macromolecular crowding treatment**

158 HDFs were seeded at a density of $15,000\text{ cells}/\text{cm}^2$ and were allowed to attach overnight
159 in basal medium comprising DMEM: Ham F12 (3:1) supplemented with 2% human
160 serum (Gibco), 10 mM HEPES, 2 mM L-glutamine, 1 mM sodium pyruvate and
161 $30\mu\text{g}/\text{ml}$ ascorbic acid (Wako Chemical; Tokyo, Japan). The medium was then replaced
162 with fresh medium containing 7.5 mg/ml Ficoll 70 (Sigma) and 25 mg/ml Ficoll 400
163 (GE Lifesciences; Buckinghamshire, UK) to induce macromolecular crowding. The
164 HDFs were cultured for 6 days for ECM deposition, with the medium changed on
165 alternate days.

166

167 **Decellularization of dermal fibroblast-derived extracellular matrix**

168 The ECMs deposited using macromolecular crowding were decellularised using either
169 EDTA (ET), ammonium hydroxide (AH) or phospholipase A_2 (PLA₂). For the ET
170 method, cells were rinsed with PBS followed by 2.5 mM EDTA/PBS, and then
171 incubated in 2.5 mM EDTA/PBS for 10 min at 37°C . Using a P1000 pipet, the cell
172 monolayer was sprayed off leaving the matrix. The matrix was washed with PBS,
173 incubated for 5 min at 37°C with 0.5% Triton X-100/PBS and washed with PBS. For
174 AH decellularisation the cells were washed with PBS and incubated in 0.02 M
175 ammonium hydroxide (Sigma)/0.5% Triton X-100/1x EDTA-Free protease inhibitor

176 (Roche; Basel, Switzerland) at 37°C for 5 min. For the PLA₂ method the cells were
177 washed in PBS and incubated in PLA₂ (20 U/ml) (Sigma)/50 mM Tris-HCl (pH 8)/0.15
178 M NaCl/1 mM MgCl₂/1 mM CaCl₂/0.5% sodium deoxycholate/1x EDTA-Free
179 protease inhibitor (Roche) at 37°C for 30 min. Matrices decellularised by the AH and
180 PLA₂ methods were then washed with PBS before being treated with 0.02 mg/ml
181 DNase I (Amresco, PA, USA) in reaction buffer (10 mM Tris-HCl (pH 7)/2.5 mM
182 MgCl₂/0.5 mM CaCl₂) at 37°C for 30 min and then washed again with PBS. The
183 presence of DNA in decellularized ECM was determined by staining with 4',6-
184 diamidino-2-phenylindole (DAPI; Sigma; 1µg/ml in PBS), while the presence of
185 residual actin was determined by staining with 1 unit/ml of phalloidin conjugated with
186 tetramethylrhodamine (TRITC). Images were captured using a Zeiss LSM510 inverted
187 fluorescent microscope. In addition to visualizing DNA using DAPI, residual nucleic
188 acids in the decellularized ECM were measured using the CyQUANT cell proliferation
189 assay kit (Molecular Probes, Thermo Fisher Scientific), following the manufacturer's
190 protocol. Fluorescence intensity was measured with 485 nm/535 nm filters using an
191 EnSpire Multimode Plate Reader (Perkin Elmer; MA, USA).

192

193 **Immunocytochemistry analysis**

194 Immunofluorescent staining was performed on cells or ECM adhered to etched glass
195 coverslips in 24-well plates. Coverslips were prepared as described in Chaturvedi *et*
196 *al*[21]. The cell or ECM layer was fixed with 4% paraformaldehyde in PBS for 15 min
197 at RT, washed with PBS then blocked with 10% Goat Serum/1% BSA/PBS for 1h at
198 RT. Blocking solution was removed, and samples were incubated for 1 h at RT with
199 primary antibody prepared in 10% Goat Serum/1% BSA/PBS. Cells were washed 3 x
200 5 min with PBS before being incubated for 1 h with secondary antibodies prepared in

201 10% Goat Serum/1% BSA/PBS. The ECMs were washed 3 x 5 min with PBS and
202 incubated in DAPI (1µg/ml in PBS) for 10 min. Coverslips were mounted in
203 Vectashield antifade mounting medium (Vector Laboratories; Peterborough, UK) and
204 sealed with nail varnish. Images were captured with either a Zeiss Axioskop
205 Fluorescent Microscope (Carl Zeiss, Germany) using Spot Advanced software
206 (Michigan, USA) or a Nikon A1+ Confocal Microscope (Nikon, Tokyo, Japan). All
207 antibodies were titrated to determine their appropriate concentration for the experiment.
208 To generate a 3D representation of the matrix, Z-stacked images of anti-Type I
209 Collagen antibody stained ECM were obtained using a Nikon A1+ Confocal
210 Microscope and images were merged using the NIS-Elements AR analysis software.

211

212 **Keratinocyte Proliferation**

213 The proliferation of keratinocytes on the substrates (Fib-Mat, type I collagen (3 µg/cm²)
214 and tissue culture plastic (TCP) was assessed. Keratinocytes were harvested and seeded
215 at a density of 1 x 10⁴ cells/well in a 48-well tissue culture plate (NUNC, ThermoFisher
216 Scientific) and grown for six days. At 24 h intervals keratinocytes were fixed for 5 min
217 with cold acetone:methanol (1:1), washed with PBS and incubated with PBS/1%BSA
218 for 1 h at RT before the nuclei were stained with DAPI (Sigma). Using an Olympus IX-
219 81 high content screening inverted microscope (Olympus; Tokyo, Japan) and a 10x
220 objective, 7 by 11 non-overlapping quadrants were imaged, to produce a 0.5 cm² area
221 image. Nuclei/cell numbers were determined using Fiji-Image J software and its “Find
222 Object” macro.

223

224

225

226 **Keratinocyte Adhesion to Substrates**

227 Cell adhesion assays were performed in 96 well tissue culture plate (NUNC).
228 Keratinocytes were harvested, resuspended in adhesion assay buffer (DMEM (Gibco),
229 10 mM HEPES (Gibco), 2 mM L-glutamine (Gibco), 1 mM sodium pyruvate (Gibco),
230 0.2% BSA (Sigma), 25 µg/ml adenine (Sigma), 0.4 µg/ml hydrocortisone (SOLU-
231 CORTEF®, Pfizer; NY, USA), 0.12 IU/ml insulin (Humulin®, Lilly; IN, USA), and
232 seeded at a density of 1×10^4 cells/well and left to adhere for 1 h at 37°C to either
233 decellularized HDF ECM, type I collagen ($3 \mu\text{g}/\text{cm}^2$) or TCP. Unbound cells were
234 removed by washing with adhesion assay buffer followed by PBS. The plate was placed
235 overnight at -80°C and brought up to RT before cell number was determined using the
236 CyQUANT cell proliferation assay kit (Molecular Probes, Invitrogen), following
237 manufacturer's instructions. Fluorescence intensity was measured with 485nm/535nm
238 filter using an EnSpire Multimode Plate Reader (Perkin Elmer). Results were calculated
239 as a percent of the control, which was prepared by pelleting 1×10^4 keratinocytes,
240 washing and storing the pellet at -80°C before using the CyQuant assay kit to determine
241 the fluorescence intensity of this number of keratinocytes.

242

243 **Keratinocyte Size and Motility**

244 Keratinocytes were harvested and seeded (1×10^4 cells/well) on the various substrates
245 in the wells of a 48-well culture plate (NUNC). After three days of culture in DKSFM
246 keratinocytes were fixed with 4% paraformaldehyde/PBS for 15 min at RT, incubated
247 in PBS/1%BSA for 1 h at RT before polymerized actin was stained with 1 unit/ml of
248 Phalloidin-Alexa 488 (Molecular Probe) and nuclei with DAPI. Using an Olympus IX-
249 81 high content screening inverted microscope (Olympus), 8 by 8 non-overlapping

250 quadrants were imaged using a 20x objective lens. Cell size as delineated by the stained
251 actin cytoskeleton was determined using the Cell Profiler software.

252

253 Keratinocyte movement was assessed on either Fib-Mat, type I collagen coating or
254 uncoated TCP. Keratinocytes were seeded as described and following an overnight
255 incubation to allow cell adhesion, live images were taken using an Olympus IX-81 high
256 content screening inverted microscope (Olympus). Time-lapse images were taken at
257 15-min intervals over 2 days using a 10x objective.

258

259 **Quantification of Ki67 Positive Keratinocytes**

260 Briefly, keratinocytes were harvested and then seeded as described above and at day 3,
261 keratinocytes were fixed with 4% paraformaldehyde for 15 min at RT, permeabilized
262 with cold 0.1% Triton X-100/PBS for 3 min and then incubated in PBS/1% BSA for 1
263 h at RT. The keratinocytes were blocked with 10% Goat Serum/1% BSA/PBS for 1 h
264 at RT before being incubated with a 0.3 µg/ml anti-Ki67 antibody (Novacastra). This
265 was followed by a 1 h incubation with Alexa 488 conjugated anti-mouse antibody at
266 RT. Keratinocyte nuclei were stained using DAPI. Images were taken on the Olympus
267 IX-81 high content screening inverted microscope. Using a 10x objective, 7 by 11 non-
268 overlapping quadrants were imaged. The percent of keratinocytes positive for Ki67 was
269 determined using the Cell Profiler software.

270

271 **Quantification of p63 Positive Keratinocytes**

272 Keratinocytes were seeded onto the different substrates and cultured for 3 days after
273 which they were fixed, permeabilised and blocked as described for the Ki67 expression
274 experiment. Keratinocytes were then incubated with 0.5µg/ml of anti-p63 mAb and the

275 anti-mouse Alexa 546 conjugated antibody, washed and the slides mounted in a DAPI-
276 containing anti-fade mounting medium. A Nikon A1+ confocal microscope and a 10x
277 objective lens was used to image 3 by 3 non-overlapping quadrants per slide. The
278 percent of p63 positive keratinocytes was determined using Cell Profiler software.

279

280 **Colony Forming Efficiency Assay**

281 Keratinocytes were grown on acellular HDF-derived ECM, type I collagen coating or
282 uncoated TCP for 3 days in DKSFM, before being harvested. Keratinocytes (1×10^3)
283 from each substrate were seeded into 6-well tissue culture plates containing mitomycin-
284 treated 3T3-J2 feeder cells and cultured for 10-12 days in culture medium which was a
285 3:1 ratio of DMEM (Gibco) and Ham's F12 (Gibco) supplemented with 10 mM
286 HEPES (Gibco), 2 mM L-glutamine (Gibco), 1 mM sodium pyruvate (Gibco), 25 μ g/ml
287 adenine (Sigma), 0.4 μ g/ml hydrocortisone (SOLU-CORTEF®, Pfizer), 0.12 IU/ml
288 insulin (Humulin®), 2 nM triiodothyronine (Sigma), 10 ng/ml epidermal growth factor
289 (BD Bioscience) and 5 mM forskolin (Sigma). Media changes were performed on
290 alternate days. After 10-12 days the cells were fixed with (1:1) acetone: methanol and
291 stained with 0.1% toluidine blue in ddH₂O. The colonies that formed were counted,
292 with colonies $\geq 1 \text{ mm}^2$ being “large” and the rest “small”.

293

294 **Mass Spectrometry and Proteomics Analysis**

295 Dermal fibroblast-derived ECMs were generated using macromolecular crowding and
296 decellularized using PLA₂. To solubilize the acellular ECM, 8 M Urea/50 mM Tris-
297 HCl pH 8.0 was added before scraping the matrix off the surface and transferring it to
298 a microtube. The matrix mixture was reduced with 10 mM DTT (Sigma), alkylated
299 with 55 mM Iodoacetamide (Sigma) and then diluted with 100 mM TEAB buffer to

300 reach a Urea concentration of < 1 M. The matrix proteins were digested with
301 sequencing grade endoproteinase Lys-C (Promega, WI, USA) and sequencing grade-
302 modified trypsin (Promega) at a ratio of 1:100 at 25⁰ C for 4 h and 18 h respectively,
303 samples were subsequently acidify with 1% TFA and desalted. Following desalting
304 with a Sep-Pak C18 column cartridge (Waters, Milford MA), the samples were
305 analysed using an Easy nLC 1000 liquid chromatography system (Thermo Fisher
306 Scientific) coupled to an Orbitrap Fusion Mass Spectrometer (Thermo Fisher
307 Scientific). Each sample was analyzed in a 60 min gradient using an Easy Spray
308 Reverse Phase Column (50 cm x 75 µm internal diameter, C-18, 2 µm particles, Thermo
309 Fisher Scientific). Data were acquired in -3 s cycle with the following parameters: MS
310 in Orbitrap and MS/MS in ion trap with ion targets and resolutions (OT-MS 4 x E5
311 ions, resolution 120 K, IT-MS/MS 1000 ions/turbo scan, “Universal Method”).

312 Data analysis: The peak list was generated using Proteome Discoverer (Version 1.4.
313 Thermo Fisher Scientific). The MS/MS spectra were searched with the Mascot 2.5.1
314 (Matrix Science, MA, USA) search algorithm using the Human UniProt Database. The
315 following parameters were used: precursor mass tolerance (MS) 20 ppm, IT-MS/MS
316 0.6 Da, 3 missed cleavages; Variable modifications: Oxidation (M), Deamidated (NQ),
317 Acetyl N-terminal protein, Static modifications: Carboamidomethyl (C).
318 Forward/decoy search was used for false discovery rate (FDR) estimations on
319 peptide/PSM level, and were set at high confidence, FDR 1% and medium confidence,
320 FDR 5%. The generated protein list was curated using the Matrisome[22] database.

321

322 **Statistical Analyses**

323 Statistical analyses were performed using SPSS statistics software V22.0 (IBM
324 Corporation, NY). If the data sets were normally distributed and their variances

325 homogeneous, a parametric test was conducted; if not, a non-parametric test was used.
326 A p-value of $p \leq 0.05$ was considered statistically significant. For normally distributed
327 data, experiments containing two treatments data sets were analysed with a t-test. For
328 experiments containing 3 or more treatment data sets, one-way analysis of variance
329 (ANOVA) was conducted followed by Tukey's posthoc test. As p63 expression data
330 were not normally distributed, these were analysed using the Kruskal-Wallis one way
331 analysis of variance followed by Wilcoxon's signed-ranked test.

332

333 **Results**

334 **Development of an Acellular Dermal Fibroblast-Derived Matrix**

335 To produce a matrix that best mimics the microenvironment of keratinocytes would
336 encounter *in vivo*, primary human dermal fibroblasts (HDFs) from adult donors were
337 chosen as the cell source. Phase contrast microscopy revealed that the HDFs used had
338 a uniform spindle-like morphology that is typical of fibroblasts. Immunofluorescence
339 analyses indicated they expressed the fibroblast markers TE-7, thy-1 and vimentin
340 (Fig. S1).

341

342 It was reported that the addition of a mixture of Ficoll 70 and Ficoll 400 to the culture
343 medium has the effect of mimicking the space occupied by glycoproteins in plasma,
344 and this was found to benefit ECM deposition by cells *in vitro*[17]. Accordingly, the
345 Ficoll cocktail was included in the fibroblast culture medium to act as MMC. The
346 Ficoll cocktail marginally altered the appearance of the HDFs, and reduced their
347 proliferation over a 7 day period (Fig. S2A, C). However, absent immunoreactivity
348 with an α -SMA antibody indicated the HDFs had not differentiated into
349 myofibroblasts. In contrast, when the Ficoll cocktail was omitted and the cells were

350 cultured for 7 days α -SMA staining was detected, and cell morphology of the α -SMA
351 positive cells resembled that of myofibroblasts (Fig. S2B). Immunostaining of the
352 ECM deposited when HDFs were cultured with the Ficoll MMC for 7 days revealed
353 an increase in the staining intensity of type I collagen, type IV collagen, fibronectin
354 and perlecan compared to cultures without MMC (Fig. 2A). When visualized with
355 confocal microscopy, a layer of type I collagen was seen fully embedding HDFs in
356 MMC culture, also covering the top of the cells, whereas cultures without MMC had
357 markedly less type I collagen staining (Fig. S3A). Removal of the HDFs using a
358 phospholipase A₂ (PLA₂) decellularisation technique revealed that type I collagen and
359 fibronectin were deposited uniformly across the surface when HDFs were cultured
360 with MMC, when compared to cultures without MMC (Fig. S3B).

361

362 As macromolecular crowding enabled a well-structured and uniform deposition of
363 ECM, without myofibroblast differentiation, MMC were used to generate the Fib-Mat.
364 To determine a decellularisation method which removed the cells, yet preserved the
365 ECM proteins and structure as much as possible, three decellularisation protocols were
366 compared. These were: EDTA, ammonium hydroxide (AH) and PLA₂. Phase contrast
367 microscopy revealed all three protocols removed the fibroblasts. However, fibril-like
368 structures were retained only with AH and PLA₂ treatments (Fig. S4). DAPI staining
369 of the nucleic acids remaining after decellularisation indicated both the EDTA and the
370 PLA₂ methods more effectively removed DNA than the AH method, which left distinct
371 nuclear fragments in the ECM (Fig. S5Ai). Quantification of DNA removal indicated
372 that the EDTA and PLA₂ methods were effective in removing 99% of the DNA,
373 whereas 97% of the DNA was removed with the AH method (Fig. S5Aii). To determine
374 whether the cytoskeletal components of the HDFs were removed following

375 decellularisation, phalloidin-TRITC staining was used to detect actin filaments. As
376 shown in Figure S5B, a few actin filament fragments were detected following AH
377 treatment, but no staining was apparent when EDTA or PLA₂ treatments were used.

378

379 To investigate the structure of the ECM following decellularisation, 3D Z-stacked
380 confocal images were obtained following type I collagen immunostaining. Fibrillar
381 structures of type I collagen resembling the non-decellularised control were clearly
382 visible following AH and PLA₂ treatments, but the EDTA treatment disrupted the
383 structure of the type I collagen filaments (Fig. 2B). The thickness of the ECM was
384 measured by determining the depth of type I collagen staining was 9 µm thick. After
385 decellularisation using the AH or PLA₂ protocols, ECM thickness decreased to around
386 6 µm, which dropped further to 3 µm following EDTA treatment (Fig. 2C).
387 Immunofluorescence intensities of the variously decellularised matrices revealed a
388 significant reduction in type I collagen and fibronectin staining after EDTA treatment.
389 In contrast, both AH and PLA₂ treatments were shown to preserve type I collagen and
390 fibronectin immunostaining (Fig. S6).

391

392 **Dermal Fibroblast Matrices Mimics Skin Dermis Extracellular Matrix**

393 Collectively the data demonstrated that the PLA₂ decellularisation protocol produced
394 an intact ECM that was devoid of most cell components, hence this method was used
395 to generate acellular matrices (Fib-Mat) for further analyses. As the goal was the
396 production of an acellular matrix that mimicked the dermal ECM, the protein
397 compositions of the ECM derived *in vitro* from two dermal fibroblast donors were
398 determined using mass spectrometry (MS)-based proteomics. To investigate whether
399 the ECM produced *in vitro* by dermal fibroblasts matched dermal ECM, the ECM

400 signature of the dermis was obtained from the “Human Protein Atlas” database[23]
401 and was compared to our proteomic data. However, after examination of the “Human
402 Protein Atlas”, it was apparent that a number of core ECM proteins like collagen III
403 alpha 1 (COL3A1) and laminin alpha-4 (LAMA4), which are present in the dermis,
404 were not found in the “Human Protein Atlas” database. To ensure a comprehensive
405 list of dermal ECM proteins was used for the comparison, the proteomic dataset of the
406 skin prepared from studies by Bliss *et al.*[24] was used to supplement the “Human
407 Protein Atlas” database. To curate the ECM proteins, the proteomic analyses and the
408 “Human Protein Atlas” supplemented data were categorised using the human
409 matrisome database (MatrisomeDB, <http://matrisomeproject.mit.edu/>). This database
410 categories the ECM proteins into “core matrisome” (ECM glycoproteins, collagens
411 and proteoglycans) and “matrisome-associated proteins” (ECM-affiliated proteins,
412 ECM regulators and secreted factors)[22]. This analysis revealed that most of the core
413 matrisome proteins expressed in the skin dermis were also found in the Fib-Mat that
414 were prepared (Fig. 3). However, the majority of the matrisome-associated proteins
415 were absent in these Fib-Mat (Fig. 3).

416

417 **Dermal Fibroblast-Derived Matrix Supports Keratinocyte Proliferation**

418 Next, the ability of Fib-Mat to support the adhesion and proliferation of keratinocytes
419 was investigated. Type I collagen was used as a positive control, as this is the substrate
420 commonly used with defined keratinocyte serum free medium (DKSFM) for
421 propagating keratinocytes[6, 7]. Tissue culture plastic (TCP) was the negative control.
422 The extent of keratinocyte adhesion to the different substrates differed. More
423 keratinocytes attached to Fib-Mat (84%), than to type I collagen (77%) or TCP (56%;
424 Fig. 4A). Phase contrast microscopy revealed that keratinocytes adhered well to both

425 Fib-Mat and type I collagen but less to TCP. While keratinocytes proliferated on all
426 three substrates, their behaviour differed. On Fib-Mat keratinocytes grew as colonies,
427 and cells within the colonies had a small cobblestone morphology, which persisted
428 until day 6 whereupon a near confluent monolayer was reached. Although similar
429 behaviour was observed on TCP, the keratinocytes comprised a heterogeneous
430 population of differing sizes. Whereas, keratinocytes on type I collagen grew as single
431 cells, they also have a mixed population, with some of the cells being large and flat
432 (Fig. 4B & Fig. 6A).

433

434 The rate of keratinocyte proliferation on the different substrates also differed. On Fib-
435 Mat keratinocytes initially proliferated more slowly than keratinocytes on type I
436 collagen but reached similar numbers by day 3. Thereafter, an exponential rate of
437 proliferation was observed in keratinocytes on Fib-Mat, which was higher than that
438 seen on type I collagen. On TCP, keratinocyte proliferation was slow and the rate
439 plateaued by day 4 (Fig. 4C). Keratinocyte expression of Ki67 was determined on day
440 3, as the growth curve (Fig. 4C) indicated a change in proliferation rates on each of
441 the substrates at this point. More keratinocytes on Fib-Mat (84.85%) stained with the
442 Ki67 mAb compared to that seen in keratinocytes on type I collagen (66.31%) and
443 TCP (56.66%; Fig. 4D). Determination of the numbers of Ki67 expressing cells on
444 day 4 and 5 revealed this remained the case (data not shown). From these data Fib-
445 Mat was the best substrate to promote keratinocyte proliferation.

446

447

448

449 **Keratinocytes Grown on Dermal Fibroblast-Derived Matrix were**
450 **Undifferentiated**

451 To determine differentiation status, keratinocytes grown on the different substrates
452 were immunostained for K16, K14, K10, and involucrin. To acquire better image
453 resolution at high magnification, etched glass coverslips (EGC) were used. To check
454 if this growth surface affected keratinocyte behaviour, keratinocytes were grown on
455 either TCP or EGC coated with Fib-Mat or type I collagen, or were uncoated. Cells
456 were grown for 3 days before being fixed and immunostained for K14. Keratinocytes
457 grown on all surfaces were similarly positive for K14 (Fig. S7). On EGC coated with
458 type I collagen, keratinocytes grew as colonies, whereas they grew as single cells on
459 TCP coated with type I collagen. As this was the only change, immunostaining of the
460 differentiation markers was performed on keratinocytes grown on EGC with, or
461 without, the various coatings. Although K14 expression was observed in keratinocytes
462 on all substrates a population of keratinocytes on uncoated EGC did not express K14
463 (Fig. 5A). While the expression of K10 was not observed in keratinocytes on any
464 substrate, involucrin expression was detected in cells on all substrates. However, a
465 higher proportion of keratinocytes were positive for involucrin when grown on
466 uncoated EGC, as compared to keratinocytes on Fib-Mat or type I collagen. In
467 addition, A higher proportion of keratinocytes grown on type I collagen and EGC
468 compared to keratinocytes grown on Fib-Mat were observed to express K16 (Fig. 5A).

469

470 Keratinocytes on each of the substrates were also examined for p63 expression, a
471 marker of “stemness”. As is shown in Figure 5B, while p63 expression was detected
472 in keratinocytes on all substrates, the number of cells expressing p63 differed. The
473 number of p63 expressing cells was significantly ($p < 0.01$) higher on Fib-Mat

474 (93.98%) and type I collagen (95.11%) than on TCP (85.48%) and the percentage of
475 p63 positive cells was similar on both Fib-Mat and type I collagen (Fig. 5Bii).

476

477 Keratinocytes grown on Fib-Mat appeared to be smaller than keratinocytes similarly
478 cultured on type I collagen or TCP (Fig. 6Ai). An assay was established based on
479 Haase *et al.*[25], where cell size was determined by the area covered by the cell.
480 Analysis of the size of individual keratinocytes revealed a statistically significant
481 difference ($p \leq 0.05$) in the size of keratinocytes grown on Fib-Mat or type I collagen.
482 The majority of keratinocytes residing on Fib-Mat were small cells, whilst type I
483 collagen had the greatest number of large flat keratinocytes (Fig. 6B). While there
484 were differences in size between cells on Fib-Mat and TCP, the differences were not
485 statistically significant.

486

487 To evaluate the self-renewal capability of keratinocytes grown on different substrates,
488 their colony forming ability was examined. Keratinocytes grown on either Fib-Mat,
489 type I collagen or TCP were harvested, then seeded onto a layer of mitomycin-c treated
490 feeder cells and grown for 12 days. The number of large colonies produced by
491 keratinocytes grown on Fib-Mat was significantly higher ($p < 0.01$) than that seen for
492 keratinocytes from either type I collagen or TCP. Furthermore, more colonies
493 regardless of size were observed in cultures of keratinocytes from the Fib-Mat (Fig. 7).

494

495 **Keratinocytes are Highly Motile on Dermal Fibroblast-Derived Matrix**

496 Cells were seeded onto EGC or TCP either uncoated, or coated with Fib-Mat or type I
497 collagen, and left overnight to adhere before time-lapse images were taken at 15-minute
498 intervals over a 2 day period. Distinct keratinocyte colonies were only seen when cells

499 were on uncoated EGC or TCP. Pseudo-colonies, where keratinocytes migrated as a
500 group of cells to form a colony, but then dispersed or combined with other colonies,
501 were observed for cells on Fib-Mat regardless of the underlying surface. Keratinocytes
502 on type I collagen coated EGC also formed pseudo-colonies, whereas on TCP coated
503 with type I collagen, keratinocytes migrated as single cells. The majority of
504 keratinocytes grown on either surface coated with Fib-Mat were highly motile over the
505 entire 2 day period. Initially keratinocytes were similarly motile on type I collagen
506 coated EGC or TCP, but as time progressed a proportion became less motile, and
507 reduced motility was accompanied by an increase in cell size. Keratinocytes on
508 uncoated EGC or TCP were the least motile, and an increase in cell size was also
509 observed. (Links to videos are in supplementary information.)

510

511 Cell motility is linked to the organization of the actin cytoskeleton. To examine the
512 arrangement of filamentous actin (F-actin) keratinocytes were grown on Fib-Mat, type
513 I collagen or EGC for 3 days before being stained with phalloidin-Alexa Fluor® 488.
514 On type I collagen and EGC, well-developed actin stress fibres were observed at the
515 keratinocyte circumference. This was more prominent in the large keratinocytes. In
516 contrast, stress fibres at the cell circumference were less visible in keratinocytes on
517 Fib-Mat (Fig. 6Aii).

518

519

520

521

522

523

524 **Discussion**

525 The regenerative ability of keratinocyte stem cells has been known since the 1980s
526 and has been well described in numerous studies[26-30]. However, the expansion of
527 keratinocytes *in vitro* for clinical use has remained challenging, as it is dependent on
528 harvesting a sufficient numbers of keratinocyte stem cells and their survival during
529 propagation. The traditional “Rheinwald and Green method” uses murine feeder cells
530 and FBS[4] and although this system has been used successfully it will face future
531 hurdles as regulators embrace xenogeneic free systems as the norm for producing cells
532 for clinical use. Keratinocytes can be expanded *in vitro* using a defined serum-free
533 medium, and a collagen matrix to support cell attachment and growth[6, 7, 31],
534 however, prolonged culture of keratinocytes in this way induces phenotypic changes;
535 specifically a diminished capacity for self-renewal and an increased commitment
536 towards terminal differentiation or senescence[7, 32, 33]. A critical factor for the
537 long-term expansion of keratinocyte stem cells is their natural microenvironmental
538 niche[8] and a key component of this niche that is lacking in the current defined culture
539 system is a native ECM. In an effort to recapitulate a similar niche that the
540 keratinocytes inhabit *in vivo*, we developed a method to generate a xenogeneic free
541 dermal Fib-Mat (Fig. 1). This Fib-Mat substrate and defined serum-free medium better
542 supported the proliferation of undifferentiated keratinocytes, compared to cultures of
543 the same keratinocytes in defined serum-free medium on substrates of type I collagen
544 or tissue TCP.

545

546 While the production and use of cell derived matrices to support the proliferation of
547 undifferentiated stem cells has been employed previously [14, 16, 34-37], the
548 generation of xenogeneic-free Fib-Mat using a tissue culture process that includes

549 macromolecular crowding during the deposition of the ECM, and PLA₂ for
550 decellularisation, is novel. The inclusion of macromolecular crowding reagents in the
551 primary dermal fibroblast xenogeneic-free cultures was found to reproducibly produce
552 matrices that completely covered the surface of the culture plates. The PLA₂
553 decellularisation protocol generated the most acceptable acellular matrices in terms of
554 absence of immunological relevant remnants, and ECM structure preservation.
555 Proteomics analysis of Fib-Mat generated under PLA₂ had a core matrisome protein
556 composition that was similar to that reported for the dermis [38, 39]. Interestingly,
557 compared to proteomic data derived from skin dermis, the Fib-Mat lacked many of
558 the matrisome-associated proteins. As some of the matrisome-associated proteins
559 actually are cell-associated proteins (e.g. LGALS1, LGALS3 & GPC1) present in a
560 full skin biopsy, it would be therefore be absent in the decellularised Fib-Mat as the
561 cells were removed. Furthermore, as Fib-Mat is the result of a monolayer culture of
562 fibroblasts, ECM proteins contributed by other residential cells (e.g keratinocyte &
563 melanocyte) within the skin dermis will also be absence.

564

565 The ability of Fib-Mat to support proliferation of keratinocytes in the serum-free
566 medium, DKSFM, was compared to similar cultures on type I collagen, the
567 recommended substrate for use with DKSFM for keratinocyte propagation[6, 7] with
568 TCP and no protein coating being the negative control. Keratinocytes adhered better
569 to Fib-Mat compared to their adhesion on type I collagen or TCP. Greater keratinocyte
570 proliferation as determined by cell number and Ki67 expression occurred on Fib-Mat,
571 compared to keratinocytes on the other substrates. These data agree with other studies
572 using stem cells. These other studies reported that cell-derived matrices which
573 matched the tissue microenvironment of the cells *in vivo* better supported the

574 attachment and proliferation of mesenchymal stem cells[40-42] and synovium-derived
575 stem cells [43, 44]. We observed an initial lag in the proliferation of keratinocytes on
576 Fib-Mat, before an exponential increase in proliferation occurred. As Fib-Mat is a
577 complex biological substrate compared to type I collagen, the acclimatisation of
578 keratinocytes towards this substrate may explain the initial slow proliferation rate.

579

580 Keratins are expressed by keratinocytes in a site-specific and differentiation-
581 dependent manner. *In vivo* K14 is expressed in keratinocytes in the basal layer of the
582 epidermis. However, as keratinocytes differentiate and migrate towards the surface of
583 the epidermis, K14 expression is downregulated[45, 46]. Studies assessing the *in vitro*
584 culture of keratinocytes in which K14 has been knocked down, showed decreased K14
585 expression was associated with reduced cell proliferation and an increase in the
586 differentiation markers K10 and involucrin[47, 48]. In our study, K14 was expressed
587 by keratinocytes grown on all three substrates, however there were a small proportion
588 of keratinocytes on EGC without K14 staining (Fig. 5A). No K10 expression was
589 observed regardless of the substrate the keratinocytes were cultured on. In contrast,
590 involucrin was expressed by keratinocytes grown on all substrates, with a higher
591 proportion of keratinocytes being involucrin-positive on uncoated EGC. The loss of
592 K14 and the increased involucrin expression coincided with decreased keratinocyte
593 proliferation on TCP/EGC. These data suggest that keratinocytes on TCP/EGC are
594 more prone to initiating differentiation in the absence of stratification, whereas the
595 continued K14 expression by keratinocytes residing on Fib-Mat is consistent with their
596 preserved growth potential. However, K14 expression was not tightly associated with
597 cell proliferation rates because there was no apparent decrease in K14 expression,
598 despite reduced keratinocyte proliferation on type I collagen (Fig 4-5).

599

600 The pattern of K16 expression was informative, as very few keratinocytes grown on
601 the Fib-Mat expressed this keratin whereas on the other substrates a high proportion
602 of cells were K16 positive. K16 expression is associated with keratinocyte
603 proliferation and migration and this keratin has been described as a marker of
604 “stressed” or activated keratinocytes[49]. Keratin 16 is commonly expressed by
605 keratinocytes in hyperproliferative diseases like psoriasis, squamous carcinoma and in
606 wound healing. Indeed, within 6 h of wounding epithelial cells at the wound edge
607 upregulate K16 expression and down regulate K10 expression[50] and these K16
608 expressing keratinocytes are involved in re-epithelization of wound site. From our data
609 it is clear that K16 expression can be uncoupled from proliferation. Moreover, the low
610 level of K16 expression by keratinocytes on Fib-Mat indicates that despite their
611 increased proliferation these cells are not mimicking a wound healing response.

612

613 A functional link between p63 expression and keratinocyte stem cell maintenance
614 within the skin has been shown by Mills *et al.*[51] and Yang *et al.*[52] using a p63-/-
615 mouse. Further studies by Parsa *et al.*[53] showed that p63 expression is restricted to
616 keratinocytes with high proliferative potential that reside within the basal layer. They
617 also found that p63 is absent from terminally differentiating keratinocytes. Our study
618 found most keratinocytes grown on Fib-Mat or type I collagen expressed p63,
619 whereas, fewer keratinocytes expressed p63 when cultured on TCP (Fig. 5B).
620 Interestingly, p63 expression coincided with a decline in growth potential (Fig. 4C)
621 and an increase in involucrin expression (Fig. 5A). This inability of TCP to support
622 the growth of undifferentiated keratinocytes is consistent with the data of others[6].

623

624 Numerous investigator have described cell size as a criteria distinguishing
625 keratinocyte stem cells from keratinocytes committed towards differentiation[8, 54,
626 55]. Moreover, increased size is associated with differentiation, a characteristic that
627 has been observed *in vivo* during normal epithelial maturation and in *in vitro* cultures
628 [7]. Hence, the change in keratinocyte size, may indicate keratinocytes undergoing
629 terminal differentiation, as keratinocyte enlargement accompanied by the expression
630 of involucrin has been reported [56, 57]. Other studies also found that small
631 keratinocytes are undifferentiated and retain a high proliferative capability[54, 55, 58].
632 We found more small keratinocytes were present in cultures grown on Fib-Mat (85%),
633 whereas culturing the same keratinocyte population on type I collagen produced larger
634 cells (Fig. 6). These data were consistent with what Esteban-Vives *et al.*[7] reported.
635
636 Recently Nanba *et al.*[59] suggested that cell motility is an attribute of undifferentiated
637 keratinocytes. They found keratinocyte colonies with a high rotational movement, and
638 in which individual cells were very motile, was indicative of these colonies containing
639 undifferentiated keratinocytes with high proliferative capability. We found
640 keratinocytes grown on Fib-Mat to be very motile (See video in supplementary
641 information). Distinct keratinocyte colonies formed only on TCP, whereas pseudo-
642 colonies formed on Fib-Mat and type I collagen. Most keratinocytes grown on Fib-
643 Mat were highly motile throughout the experiment, but keratinocytes cultured on type
644 I collagen and TCP were less motile, a trait very evident when the time in culture was
645 extended. Moreover, the reduced motility of individual keratinocytes was
646 accompanied by an increase in cell size. The association of increased size, with
647 decreased motility during keratinocyte differentiation was reported many years ago by
648 Sun *et al.*[56] and our results are consistent with these findings.

649

650 Actin filament reorganisation is essential for changes in cell shape and motility. In our
651 study keratinocytes plated on type I collagen or EGC without a matrix protein coating
652 developed a circumferential actin network (Fig. 6Aii), similar to that reported by
653 Nanba *et al.*[60] and which was described to be indicative of reduced cell movement
654 and terminal differentiation. In contrast, keratinocytes grown on Fib-Mat had short
655 bundles of actin that were radially distributed (Fig. 6Aii), an arrangement of actin
656 filaments described as indicative of proliferative, undifferentiated keratinocytes[60].

657

658 Collectively, our data indicate that keratinocytes grown on Fib-Mat are less
659 differentiated than keratinocytes cultured on TCP, which show signs of undergoing
660 early commitment to terminal differentiation. Whereas, despite exhibiting
661 characteristics that are indicative of differentiation (e.g. cell size, cell motility, lower
662 colony forming ability and actin reorganization) keratinocytes grown on type I
663 collagen still expressed markers (K14 and p63) of undifferentiated keratinocytes.
664 Others have also found that keratinocytes retain some markers characteristic of
665 undifferentiated cells during the early stages of differentiation. Webb *et al.*[61] found
666 that keratinocytes in the basal layer of the epidermis do not switch off the expression
667 of keratin 15 (a marker of keratinocyte quiescence, and in some circumstances of stem
668 cells) even during the differentiation process. Furthermore, Esteban-Vives *et al.*[7],
669 observed that keratinocytes grown on type I collagen still retained K15 expression
670 despite showing signs of differentiation. Hence, it is likely that on type I collagen, the
671 keratinocytes are in the early stages of terminal differentiation, even though some
672 markers of undifferentiated cells are present.

673

674 This conclusion was further supported by the behaviour of the keratinocytes expanded
675 on different substrates in a colony forming assay. Barrandon *et al.* [62] described the
676 use of colony forming assays as an invaluable tool for determining the presence of stem
677 cells within a keratinocyte population. Undifferentiated keratinocyte stem cells are
678 described to have a higher self-renewal capability and form large, progressively
679 growing colonies (> 1 mm²; holoclones). We found that keratinocytes grown on Fib-
680 Mat produced a higher number of large colonies, when compared to keratinocytes
681 expanded on the other two substrates. This indicate that Fib-Mat better retained and
682 promoted the self-renewal ability of undifferentiated keratinocyte stem cells.

683

684 Others have also shown cell-ECM interactions are important for preserving the self-
685 renewal ability of cultured keratinocytes. Adams and Watt[63] demonstrated that
686 keratinocytes losing ECM contact are triggered to terminal differentiation. Similarly,
687 our data and that of Coolen *et al.*[6], showed that keratinocytes undergo terminal
688 differentiation when grown on tissue culture plastic that lacked an ECM protein.
689 Hence, ECM proteins such as type I collagen[7], type IV collagen[6] and
690 fibronectin[64] have been used as substrates to culture keratinocytes. Although using
691 these single ECM proteins enable the keratinocytes to adhere and proliferate, they do
692 not sustain the long-term growth of keratinocytes[7, 32]. In this reductionist approach,
693 the synergistic impact of growth factors and ECM proteins and their coordinated
694 signalling pathways in the keratinocytes is overlooked. Others have shown that even
695 the combination of three matrix proteins can have a synergistic effect[65-67]. Flaim
696 *et al.*[65] found that the combination of type I collagen with laminin and type III
697 collagen enabled embryonic stem (ES) cells to efficiently differentiate towards a liver
698 progenitor lineage, although individually these matrix proteins were unable to

699 promote liver progenitor cell differentiation. Furthermore, Watt *et al.*[64] showed that
700 substrates comprising a combination of laminin, type IV collagen and fibronectin
701 inhibited the differentiation of keratinocytes during *in vitro* culture.

702

703 The proteomics data indicated that our Fib-Mat contained laminins, type IV collagen
704 and fibronectin plus numerous other ECM proteins, and some, but not all, the ECM
705 associated proteins, but very few of the secreted factors found in the dermis. Our data
706 indicate the combined signals of the core matrisome proteins that are present in Fib-
707 Mat, are sufficient to suppress keratinocyte differentiation and to promote
708 proliferation. It is not possible to say from our data that the complex mixture of
709 chemokines, growth factors and other secreted factors are also contributing to
710 suppressing keratinocyte differentiation. In our study the essential growth factors for
711 keratinocyte proliferation were probably present in the culture medium and the Fib-
712 Mat provided the ECM components to correctly present these growth factors to the
713 growing keratinocytes. However, whether essential secreted factors were present in
714 the Fib-Mat at very low concentration is unclear as the proteomics methodology may
715 not detect such proteins.

716

717 In conclusion, this study highlights the important role of a native ECM in modulating
718 keratinocyte growth and differentiation. Our novel culture system using dermal
719 fibroblast ECM is superior to current protocols for the serum-free culture of
720 keratinocytes for clinical use because it delivers undifferentiated keratinocytes that
721 continue to proliferate. In contrast, keratinocytes expanded using type I collagen (the
722 current protocol) are likely to have progressed down the terminal differentiation
723 pathway as a result of the expansion protocol used.

724 **Acknowledgements**

725 The authors are grateful to Dr. Paula Benny for her technical assistance and Mr. John
726 Lim for assisting in image analysis. The authors would also like to thank A/Prof.
727 Pritinder Kaur for her guidance in the colony formation assay and Prof. John
728 Whitelock and Dr Megan Lord for their gift of the anti-perlecan antibody, CCN-1.
729 Chee Wai Wong was supported by a Curtin University Strategic International
730 Research Scholarship. Radoslaw M Sobota was funded by IMCB, A*STAR, Young
731 Investigator Grant YIG 2015 (BMRC, A*STAR) and NMRC MS-CETSA platform
732 grant MOHIAFCAT2/004/2015. The authors acknowledge the provision of research
733 facilities and technical assistance of the staff of CHIRI Bioscience, which was partly
734 funded by Curtin University, State and Commonwealth Governments.

735

736 **Author Contribution**

737 Chee-Wai Wong: Conception and design, collection and assembly of data, data analysis
738 and interpretation, manuscript writing, final approval of manuscript.
739 Beverley F. Kinnear: Conception and design, final approval of manuscript.
740 Radoslaw M. Sobota: Conception and design, collection and assembly of data, final
741 approval of manuscript.
742 Rajkumar Ramalingam: Conception and design, collection and assembly of data, final
743 approval of manuscript.
744 Catherine F. Legrand: Collection and assembly of data, final approval of manuscript.
745 Danielle E. Dye: Conception and design, final approval of manuscript.
746 Michael Raghunath: Conception and design, final approval of manuscript.
747 E. Birgitte Lane: Conception and design, supply of research materials, financial
748 support, final approval of manuscript.


749 Deirdre R. Coombe: Conception and design, data interpretation, financial support,

750 manuscript writing, final approval of manuscript.

751

752

753



754

755 **Figure 1: Schematic of the preparation of a xenogeneic-free acellular dermal**
756 **fibroblast-derived matrix as a substrate for keratinocytes.**

757

758

759

760

761


762

763

764

765

766



767

768 **Figure 2: ECM proteins deposited by dermal fibroblasts**

769 **A)** The effect of MMC on HDF ECM deposition. The cells and matrix were
770 immunostained for type I collagen (i, v), type IV collagen (ii, vi), fibronectin (iii, vii)
771 and perlecan (iv, viii). Scale bars are 100 μm.

772 **B)** The 3D architecture of the ECM deposited by HDF before and after decellularisation
773 with EDTA, AH or PLA₂ as revealed by type I collagen immunostaining and DAPI
774 staining. Scale bars are 10 μm.


775 **C)** The thickness of the ECM after decellularisation. The colour coding represents the
776 Z-depth location within the 3D z-stacked image.

777


778

779

Core Matrisome Proteins




Matrisome Associated Proteins



780

781 **Figure 3: Protein composition of the acellular ECM.** Protein compositions of the
 782 acellular ECM from dermal fibroblasts from two donors were compared to that of the
 783 dermis. The ECM proteins are subdivided into two categories; “core matrisome” (ECM
 784 glycoproteins, collagens and proteoglycans); and “matrisome-associated proteins”
 785 (ECM-affiliated proteins, ECM regulators and secreted factors). Green and grey
 786 indicate the presence or absence of ECM proteins respectively.

787



788

789 **Figure 4: The different substrates support keratinocyte adhesion and**
 790 **proliferation to varying degrees.**


791 **A)** The ability of Fib-Mat, Col I and TCP to support keratinocyte adhesion. The data
 792 are the mean percent of bound keratinocytes \pm standard deviation; mean values are
 793 given. Shown are pooled data from three separate experiments. **= $P < 0.01$

794 **B)** Morphology of keratinocytes growing on dermal fibroblast-derived matrix (Fib-
 795 Mat), type I collagen (Col I) and tissue culture plastic (TCP) as captured by phase
 796 contrast microscopy. Keratinocyte on days 1, 4 and 6 post seeding are shown. Scale
 797 bars are 100 μm.

798 **C)** The ability of Fib-Mat, Col I and TCP to support keratinocyte proliferation. Nuclei
 799 were stained with DAPI and counted. The data are the mean \pm standard deviation
 800 obtained from 4 replicate wells. A representative of three separate experiments is
 801 shown.

802 **D)** Ki67 expression by keratinocytes cultured on Fib-Mat, Col I and TCP. The data
 803 are the mean percent of Ki67 positive keratinocytes \pm standard deviation; mean values

804 are given. The data shown are representative of three separate experiments. ** =
805 P<0.01.




806
807 **Figure 5: Expression of differentiation markers by keratinocytes grown on**
808 **different substrates.**

809 **A)** The expression of K14 (i-iii), K16 (iv-vi), K10 (vii-ix) and involucrin (x-xii) by
810 keratinocytes grown for three days on Fib-Mat, Col I and etched glass coverslips
811 (EGC). Nuclei were stained using DAPI (Blue). Scale bars are 50 μm for K14 and 100
812 μm for K10, K16 and involucrin. Arrows indicate keratinocytes with no K14
813 expression.

814 **B)** Expression of p63 by keratinocytes grown on Fib-Mat, Col I and TCP. i)
815 Representative image of keratinocytes immunostained for p63. Arrows indicate the area
816 of p63 negative keratinocytes. The nuclei were stained using DAPI (Blue) Scale bars
817 are 100 μm . ii) Quantification of keratinocytes positive for p63. The data shown are
818 representative of three separate experiments. Median values are given. Statistical
819 analyses were a Kruskal-Wallis test followed by a Mann-Whitney test. ** = P<0.01

820
821
822
823
824



825

826 **Figure 6: Size of keratinocytes grown on different substrates.**

827 A) i) Phase contrast images show differences in the size of keratinocytes grown on the
828 various substrates. Images were captured on day 3 of culture. Scale bars are 100 μm .

829 ii) Representative images of keratinocytes stained with phalloidin-Alexa Fluor[®] 488
830 demonstrating that phalloidin staining accurately revealed keratinocyte size. Scale bars
831 are 50 μm . Nuclei were stained using DAPI (Blue).

832 B) Frequency of keratinocytes of differing size. Cell size was categorised as small,
833 medium or large based on cell area (small < medium < large =
834 < 2000 μm^2 < 4000 μm^2 < 6000 μm^2). The data shown are the mean percent of total cells \pm
835 standard deviation. Pooled data from three separate experiments are shown. * = $P \leq 0.05$.

836

837

838

839

840


841

842

843

844

845



846

847 **Figure 7: Colony forming ability of keratinocytes previously cultured on different**
848 **substrates.**

849 A) Representative image of the colonies formed by keratinocytes previously cultured
850 on different substrates. Keratinocytes were cultured for three days on Fib-Mat, type I
851 collagen or uncoated TCP, the cells were harvested and single cells were seeded at low
852 density onto mitomycin treated 3T3-J2 feeder cells. After 12 days keratinocyte colonies
853 were stained with toluidine blue and imaged.

854 B) Quantification of the colonies. All colonies were counted and categorized: large
855 colonies were $\geq 1\text{mm}^2$, and small colonies were cell clusters $<1\text{mm}^2$. The data shown
856 are representative of three separate experiments. * = $P \leq 0.05$ and ** = $P < 0.01$

857

858

859

860

861


862

863

864

865

866



867


868 **Figure S1: Characterization of human dermal fibroblasts (HDF).**

869 HDF were stained with antibodies recognising the fibroblast markers: TE-7 (ii),
870 vimentin (iii) or Thy-1 (iv). The secondary antibody was an Alexa Fluor® 546-
871 conjugated anti-mouse IgG1. Nuclei were stained with DAPI (blue). Scale bars are 100
872 μm .

873

874

875




876

877 **Figure S2: The effect of MMC on fibroblast behaviour.**

878 A) Phase contrast images of HDF cultured with or without MMC. Scale bars are 100
879 μ m.

880 B) Myofibroblast differentiation with and without MMC. HDF were grown either with
881 or without MMC for seven days. The cells were stained with a mAb recognising α -
882 smooth muscle actin (α -SMA) and imaged by confocal microscopy. The secondary
883 antibody was an Alexa Fluor® 488-conjugated anti-mouse IgG2a. Nuclei were stained
884 using DAPI (Blue). Scale bars are 100 μ m.

885 C) HDF grow more slowly under MMC conditions. The number of HDFs after
886 culturing with or without MMC for seven days. Data are expressed as mean \pm SD. Mean
887 values are given. Shown is a representative of triplicate experiments. ** = $P < 0.01$.




888

889 **Figure S3: The effect of MMC on the ECM deposited by HDF**

890 **A)** The effect of MMC on the 3D architecture of the ECM deposited by HDF. A 3D Z-
891 stacked confocal image of type I collagen deposited by HDFs grown without or with
892 MMC for seven days. Cells and matrix were immunostained for type I collagen. The
893 secondary antibody was an anti-rabbit IgG Alexa Fluor® 488-conjugated antibody.
894 Nuclei were stained with DAPI (Blue). Scale bars are 10 μ m.

895 **B)** The ECM deposited by HDF with or without MMC after decellularisation. The HDF
896 were grown with or without MMC for seven days. The cell layers were decellularised
897 using PLA₂. Matrices were immunostained for type I collagen (i, ii) or fibronectin (iii,
898 iv). The secondary antibody was an Alexa Fluor® 488-conjugated anti-rabbit IgG.
899 Nuclei were stained with DAPI (Blue). Scale bars are 100 μ m.



900

901 **Figure S4: Decellularised dermal fibroblast-derived ECM prepared using EDTA,**
902 **ammonia hydroxide (AH) or phospholipase A₂ (PLA₂).** Images were obtained using
903 phase contrast microscopy. The HDF were grown with MMC for seven days and
904 decellularised as indicated. The control was HDF before decellularisation. Scale bars
905 are 100 μm .

906

907

908

909

910

911

912

913


914

915

916

917

918




919

920 **Figure S5: Efficacy of methods for decellularisation of HDF matrices.**

921 **A)** Efficacy of decellularisation methods for removing nuclear components. i) DAPI
922 staining of the variously decellularised ECM and untreated HDF control. HDF were
923 grown with MMC for seven days then decellularised by the method indicated. Images
924 were obtained using fluorescence microscopy. Scale bars are 100 μ m. ii) Quantification
925 of DNA removed after decellularisation. The CyQuant dye was used to measure the
926 DNA present following decellularisation and these fluorescent intensity values were
927 subtracted from the fluorescent intensity of the untreated control to allow calculation
928 of percent of DNA removed. Means \pm SD of 4 replicates are shown. The figure is a
929 representative of three experiments. ** = $P < 0.01$.

930 **B)** Efficacy of different decellularisation treatments for removing cytoskeletal
931 components. Phalloidin staining of the variously decellularised ECM and untreated
932 HDF control cell layer for polymerised actin. Images were obtained using fluorescence
933 microscopy. Scale bars are 100 μ m.

934



935

936

Figure S6: Quantities of the deposited ECM after decellularisation.

937

A) Representative images of ECM obtained using different decellularisation treatments: EDTA, ammonia hydroxide (AH) & phospholipase A₂ (PLA₂). The acellular ECM were immunostained using antibodies recognizing either type I collagen or fibronectin. Scale bars are 100 μ m.

941

B) Quantification of fluorescence intensity of type I collagen (i) and fibronectin (ii) immunostaining after decellularisation. Data are expressed as mean \pm SD. Mean value are shown. The figure is representative of three experiments. *= $P < 0.05$

944

945


946

947

948

949

950



951

952 **Figure S7: Comparison of tissue culture plastic (TCP) and etched glass coverslips**
953 **(EGC) as a platform for keratinocyte growth.**

954 Keratinocytes grown on either EGC or TCP coated with either Fib-Mat (i,iv), type I
955 collagen (3ug/cm²: ii,iv) or were uncoated (plain: iii, vi). Keratinocytes were cultured
956 for 3 days in DKSFM then fixed with acetone: methanol (1:1) and immunostained for
957 K14. The secondary antibody was an anti-mouse IgG Alexa Fluor® 488-conjugated
958 antibody (Green). Nuclei were stained with DAPI (Blue). Scale bars are 100μm.

959

960

961

962

963

964

965

966

967

968

969

970

971

972 **Reference**

- 973 1. Fuchs E. Scratching the surface of skin development. **NATURE**
974 2007;445(7130):834–842.
- 975 2. Chen M, Przyborowski M, Berthiaume F. Stem cells for skin tissue engineering and
976 wound healing. **CRIT REV BIOMED ENG** 2009;37(4-5):399–421.
- 977 3. Priya SG, Jungvid H, Kumar A. Skin Tissue Engineering for Tissue Repair and
978 Regeneration. **TISSUE ENGINEERING PART B: REVIEWS**
979 2008;14(1):105–118.
- 980 4. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal
981 keratinocytes: the formation keratinizin colonies from single cells. **CELL**
982 1975;6(3):331–343.
- 983 5. MacNeil S. Progress and opportunities for tissue-engineered skin. **NATURE**
984 2007;445(7130):874–880.
- 985 6. Coolen NA, Verkerk M, Reijnen L, et al. Culture of keratinocytes for
986 transplantation without the need of feeder layer cells. **CELL TRANSPLANT**
987 2007;16(6):649–661.
- 988 7. Esteban-Vives R, Young M, Over P, et al. In vitro keratinocyte expansion for cell
989 transplantation therapy is associated with differentiation and loss of basal layer
990 derived progenitor population. **DIFFERENTIATION** 2015:1–9.
- 991 8. Barrandon Y, Grasset N, Zaffalon A, et al. Capturing epidermal stemness for
992 regenerative medicine. **SEMINARS IN CELL AND DEVELOPMENTAL**
993 **BIOLOGY** 2012;23(8):937–944.
- 994 9. Peehl DM, Ham RG. Growth and differentiation of human keratinocytes without a
995 feeder layer or conditioned medium. **IN VITRO** 1980;16(6):516–525.
- 996 10. Boyce ST, Ham RG. Calcium-regulated differentiation of normal human
997 epidermal keratinocytes in chemically defined clonal culture and serum-free serial
998 culture. **J INVESTIG DERMATOL** 1983.
- 999 11. Hubmacher D, Apte SS. The biology of the extracellular matrix. **CURRENT**
1000 **OPINION IN RHEUMATOLOGY** 2013;25(1):65–70.
- 1001 12. Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance.
1002 2010;123(Pt 24):4195–4200.
- 1003 13. Peng Y, Bocker MT, Holm J, et al. Human fibroblast matrices bio-assembled
1004 under macromolecular crowding support stable propagation of human embryonic
1005 stem cells. **J TISSUE ENG REGEN MED** 2012;6(10):e74–e86.
- 1006 14. Jiang D, Xu B, Yang M, et al. Efficacy of tendon stem cells in fibroblast-derived
1007 matrix for tendon tissue engineering. **JOURNAL OF CYTOTHERAPY**
1008 2014;16(5):662–673.

- 1009 15. Ng CP, Sharif ARM, Heath DE, et al. Enhanced ex vivo expansion of adult
1010 mesenchymal stem cells by fetal mesenchymal stem cell ECM.
1011 **BIOMATERIALS** 2014;35(13):4046–4057.
- 1012 16. Zhou Y, Zimmer M, Yuan H, et al. Effects of Human Fibroblast-Derived
1013 Extracellular Matrix on Mesenchymal Stem Cells. **STEM CELL REV** 2016:1–
1014 13.
- 1015 17. Chen C, Loe F, Blocki A, et al. Applying macromolecular crowding to enhance
1016 extracellular matrix deposition and its remodeling in vitro for tissue engineering
1017 and cell-based therapies. **ADVANCED DRUG DELIVERY REVIEWS**
1018 2011;63(4-5):277–290.
- 1019 18. Kumar P, Satyam A, Fan X, et al. Macromolecularly crowded in vitro
1020 microenvironments accelerate the production of extracellular matrix-rich
1021 supramolecular assemblies. **SCI. REP.** 2015;5:8729–10.
- 1022 19. Minton AP. The Influence of Macromolecular Crowding and Macromolecular
1023 Confinement on Biochemical Reactions in Physiological Media. **JOURNAL OF**
1024 **BIOLOGICAL CHEMISTRY** 2001;276(14):10577–10580.
- 1025 20. Zeiger AS, Loe FC, Li R, et al. Macromolecular Crowding Directs Extracellular
1026 Matrix Organization and Mesenchymal Stem Cell Behavior. Tsilibary EC, ed.
1027 **PLOS ONE** 2012;7(5):e37904.
- 1028 21. Chaturvedi V, Dye DE, Kinnear BF, et al. Interactions between Skeletal Muscle
1029 Myoblasts and their Extracellular Matrix Revealed by a Serum Free Culture
1030 System. Engler AJ, ed. **PLOS ONE** 2015;10(6):e0127675–27.
- 1031 22. Naba A, Clauser KR, Hoersch S, et al. The matrisome: in silico definition and in
1032 vivo characterization by proteomics of normal and tumor extracellular matrices.
1033 **MOL. CELL PROTEOMICS** 2012;11(4):M111.014647–M111.014647.
- 1034 23. Uhlén M, Fagerberg L, Hallström BM, et al. Proteomics. Tissue-based map of the
1035 human proteome. **SCIENCE** 2015;347(6220):1260419–1260419.
- 1036 24. Bliss E, Heywood WE, Benatti M, et al. An optimised method for the proteomic
1037 profiling of full thickness human skin. **BIOLOGICAL PROCEDURES**
1038 **ONLINE** 2016:1–7.
- 1039 25. Haase I, Evans R, Pofahl R, et al. Regulation of keratinocyte shape, migration and
1040 wound epithelialization by IGF-1-and EGF-dependent signalling pathways. 2003.
- 1041 26. Gregory GG, O'Connor NE, Compton CC. *Permanent coverage of large burn*
1042 *wounds with autologous cultured human epithelium.* N Engl J Med; 1984.
- 1043 27. Dunnwald M, Tomanek-Chalkley A, Alexandrunas D, et al. Isolating a pure
1044 population of epidermal stem cells for use in tissue engineering.
1045 **EXPERIMENTAL DERMATOLOGY** 2001;10(1):45–54.
- 1046 28. Li A, Pouliot N, Redvers R, et al. Extensive tissue-regenerative capacity of
1047 neonatal human keratinocyte stem cells and their progeny. **J. CLIN. INVEST.**

- 1048 2004;113(3):390–400.
- 1049 29. Kim DS, Cho HJ, Choi HR, et al. Isolation of human epidermal stem cells by
1050 adherence and the reconstruction of skin equivalents. **CELL. MOL. LIFE SCI.**
1051 2004;61(21):2774–2781.
- 1052 30. Cerqueira MT, Frias AM, Reis RL, et al. Boosting and Rescuing Epidermal
1053 Superior Population from Fresh Keratinocyte Cultures. **STEM CELLS AND**
1054 **DEVELOPMENT** 2014;23(1):34–43.
- 1055 31. Horch RE, Debus M, Wagner G, et al. Cultured human keratinocytes on type I
1056 collagen membranes to reconstitute the epidermis. **TISSUE ENG.** 2000;6(1):53–
1057 67.
- 1058 32. Youn SW, Kim DS, Cho HJ, et al. Cellular senescence induced loss of stem cell
1059 proportion in the skin in vitro. **JOURNAL OF DERMATOLOGICAL**
1060 **SCIENCE** 2004;35(2):113–123.
- 1061 33. Strudwick XL, Lang DL, Smith LE, et al. Combination of Low Calcium with Y-
1062 27632 Rock Inhibitor Increases the Proliferative Capacity, Expansion Potential
1063 and Lifespan of Primary Human Keratinocytes while Retaining Their Capacity to
1064 Differentiate into Stratified Epidermis in a 3D Skin Model. Brandner JM, ed.
1065 **PLOS ONE** 2015;10(4):e0123651–12.
- 1066 34. Lu H, Hoshiba T, Kawazoe N, et al. Cultured cell-derived extracellular matrix
1067 scaffolds for tissue engineering. **BIOMATERIALS** 2011;32(36):9658–9666.
- 1068 35. Fitzpatrick LE, McDevitt TC. Cell-derived matrices for tissue engineering and
1069 regenerative medicine applications. **BIOMATER SCI** 2015;3(1):12–24.
- 1070 36. Xing Q, Yates K, Tahtinen M, et al. Decellularization of Fibroblast Cell Sheets for
1071 Natural Extracellular Matrix Scaffold Preparation. **TISSUE ENGINEERING**
1072 **PART C: METHODS** 2015;21(1):77–87.
- 1073 37. Zhang W, Zhu Y, Li J, et al. Cell-Derived Extracellular Matrix: Basic
1074 Characteristics and Current Applications in Orthopedic Tissue Engineering.
1075 **TISSUE ENGINEERING PART B: REVIEWS** 2016;22(3):193–207.
- 1076 38. Sorrell JM, Caplan AI. Fibroblast heterogeneity: more than skin deep.
1077 2004;117(Pt 5):667–675.
- 1078 39. Sriram G, Bigliardi PL, Bigliardi-Qi M. Fibroblast heterogeneity and its
1079 implications for engineering organotypic skin models in vitro. **EUROPEAN**
1080 **JOURNAL OF CELL BIOLOGY** 2015;94(11):483–512.
- 1081 40. Lai Y, Sun Y, Skinner CM, et al. Reconstitution of marrow-derived extracellular
1082 matrix ex vivo: a robust culture system for expanding large-scale highly
1083 functional human mesenchymal stem cells. **STEM CELLS AND**
1084 **DEVELOPMENT** 2010;19(7):1095–1107.
- 1085 41. Lin H, Yang G, Tan J, et al. Influence of decellularized matrix derived from
1086 human mesenchymal stem cells on their proliferation, migration and multi-

- 1087 lineage differentiation potential. **BIOMATERIALS** 2012;33(18):4480–4489.
- 1088 42. Rakian R, Block TJ, Johnson SM, et al. Native extracellular matrix preserves
1089 mesenchymal stem cell “stemness” and differentiation potential under serum-free
1090 culture conditions. **STEM CELL RES THER** 2015:1–11.
- 1091 43. He F, Chen X, Pei M. Reconstruction of an in vitro tissue-specific
1092 microenvironment to rejuvenate synovium-derived stem cells for cartilage tissue
1093 engineering. **TISSUE ENG PART A** 2009;15(12):3809–3821.
- 1094 44. Pei M, Zhang Y, Li J, et al. Antioxidation of Decellularized Stem Cell Matrix
1095 Promotes Human Synovium-Derived Stem Cell-Based Chondrogenesis. **STEM**
1096 **CELLS AND DEVELOPMENT** 2013;22(6):889–900.
- 1097 45. Fuchs E, Green H. Changes in keratin gene expression during terminal
1098 differentiation of the keratinocyte. **CELL** 1980;19(4):1033–1042.
- 1099 46. Coulombe PA, Kopan R, Fuchs E. Expression of keratin K14 in the epidermis and
1100 hair follicle: insights into complex programs of differentiation. **J. CELL BIOL.**
1101 1989;109(5):2295–2312.
- 1102 47. Troy TC, Turksen K. In vitro characteristics of early epidermal progenitors
1103 isolated from keratin 14 (K14)-deficient mice: insights into the role of keratin 17
1104 in mouse keratinocytes. **J. CELL. PHYSIOL.** 1999;180(3):409–421.
- 1105 48. Alam H, Sehgal L, Kundu ST, et al. Novel function of keratins 5 and 14 in
1106 proliferation and differentiation of stratified epithelial cells. **MOL. BIOL. CELL**
1107 2011;22(21):4068–4078.
- 1108 49. Gawronska-Kozak B, Grabowska A, Kur-Piotrowska A, et al. Foxn1
1109 Transcription Factor Regulates Wound Healing of Skin through Promoting
1110 Epithelial-Mesenchymal Transition. Slominski AT, ed. **PLOS ONE**
1111 2016;11(3):e0150635–21.
- 1112 50. Maruthappu T, Fell B, Delaney PJ, et al. Rhomboid family member 2 regulates
1113 cytoskeletal stress-associated Keratin 16. **NATURE COMMUNICATIONS**
1114 2017;8:1–11.
- 1115 51. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb
1116 and epidermal morphogenesis. **NATURE** 1999;398(6729):708–713.
- 1117 52. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation
1118 in limb, craniofacial and epithelial development. **NATURE** 1999;398(6729):714–
1119 718.
- 1120 53. Parsa R, Yang A, McKeon F, et al. Association of p63 with Proliferative Potential
1121 in Normal and Neoplastic Human Keratinocytes. **J. INVEST. DERMATOL.**
1122 1999;113(6):1099–1105.
- 1123 54. Izumi K, Tobita T, Feinberg SE. Isolation of human oral keratinocyte
1124 progenitor/stem cells. **JOURNAL OF DENTAL RESEARCH** 2007;86(4):341–
1125 346.

- 1126 55. Li J, Miao C, Guo W, et al. Enrichment of putative human epidermal stem cells
1127 based on cell size and collagen type IV adhesiveness. **CELL RES**
1128 2008;18(3):360–371.
- 1129 56. Sun TT, Green H. Differentiation of the epidermal keratinocyte in cell culture:
1130 formation of the cornified envelope. **CELL** 1976;9(4 Pt 1):511–521.
- 1131 57. Watt FM, Green H. Involucrin synthesis is correlated with cell size in human
1132 epidermal cultures. **J. CELL BIOL.** 1981.
- 1133 58. Barrandon Y, Green H. Cell size as a determinant of the clone-forming ability of
1134 human keratinocytes. **PROC. NATL. ACAD. SCI. U.S.A.** 1985;82(16):5390–
1135 5394.
- 1136 59. Nanba D, Toki F, Tate S, et al. Cell motion predicts human epidermal stemness. **J.**
1137 **CELL BIOL.** 2015;209(2):305–315.
- 1138 60. Nanba D, Toki F, Matsushita N, et al. Actin filament dynamics impacts
1139 keratinocyte stem cell maintenance. **EMBO MOL MED** 2013;5(4):640–653.
- 1140 61. Webb A, Li A, Kaur P. Location and phenotype of human adult keratinocyte stem
1141 cells of the skin. **DIFFERENTIATION** 2004;72(8):387–395.
- 1142 62. Barrandon Y, Green H. Three clonal types of keratinocyte with different
1143 capacities for multiplication. **PROC. NATL. ACAD. SCI. U.S.A.**
1144 1987;84(8):2302–2306.
- 1145 63. Adams JC, Watt FM. Fibronectin inhibits the terminal differentiation of human
1146 keratinocytes. **NATURE** 1989;340(6231):307–309.
- 1147 64. Watt FM, Kubler MD, Hotchin NA, et al. Regulation of keratinocyte terminal
1148 differentiation by integrin-extracellular matrix interactions. 1993;106(1):175–182.
- 1149 65. Flaim CJ, Chien S, Bhatia SN. An extracellular matrix microarray for probing
1150 cellular differentiation. **NAT METH** 2005;2(2):119–125.
- 1151 66. Flaim CJ, Teng D, Chien S, et al. Combinatorial Signaling Microenvironments for
1152 Studying Stem Cell Fate. **STEM CELLS AND DEVELOPMENT**
1153 2008;17(1):29–40.
- 1154 67. Malta DFB, Reticker-Flynn NE, da Silva CL, et al. Extracellular matrix
1155 microarrays to study inductive signaling for endoderm specification. **ACTA**
1156 **BIOMATERIALIA** 2016;34(C):30–40.
- 1157